# Minimal data set for tuberculosis in allogeneic

# hematopoietic stem cell transplantation recipients

Serial No :			Name :		
Age/Sex : /	(age at HSC	T)	Chart No :		
Underlying Dise	ease :				
$\Box$ AML	□ ALL	$\Box$ CML			
$\square$ MDS		$\Box$ Others ( )			
BMT date :					
Type of SCT					
□ Syngeneic	□ Matched-relat	ted	hed-unrelated	□ Family mis	smatch
Stem cell Source					
$\Box BM  \Box PBS  \Box BM + PBSC  \Box Cord blood$					
Conditioning re	egimen (TBI)	□ TBI based	□ No-TBI base	d	
Conditioning re	egimen (ATG)	□ ATG	□ No-ATG		
Conditioning In	itensity	□ Myeloablative	e □ Nor	-myeloablative	(mini-)
GVHD prophyl	axis				
Cyclosporine	□ Meth	notrexate	□ FK506	□ MMF	□ Others

()

Acute GVHD	□ None		□ Yes		
Overall grade :					
aGVHD date :					
Involved organ :					
Outcome	Improvement		□ Aggrav	vation	
Chronic GVHD	□ None		Limite	d	□ Extensive
cGVHD date :					
Involved organ :					
Grade	□ Mild		rate		e
Outcome	Improvement		□ Aggrav	vation	
Relapse of hema	tologic disease	□ Yes	□ No		
Relapse date :					
Death	$\Box$ Yes $\Box$ No				
Date of death :					
Cause of death :					
Last follow up da	ite :				
IGRA	Positive		ive	$\Box$ Not do	one
INH prophylaxis	s 🗆 Yes	□ No	□ Not do	ne	
If yes, duration :					
If no, the reason :					

# Events during INH prophylaxis

- $\Box$  Drug toxicity ( )
- $\hfill\square$  Relapse of hematologic disease ( )

 $\square$  Aggravation of GVHD ( )

 $\Box$  Others ( )

-----

TB after HSCT	$\Box$ Yes	🗆 No

Date of TB Diagnosis :

### Dx of tuberculosis

□ PROVEN	□ Culture, culture site :			
D PROBABLE	□ AFB Smear, site :			
	□ Tissue histology, site :			
	□ Fluid cytology, site :			
D POSSIBLE	□ Radiologic result, site :	□ Improve after anti TB medication		
	□ Not improve after antibacterial and	nd antifungal medication		
D POSSIBLE	<ul> <li>Fluid cytology, site :</li> <li>Radiologic result, site :</li> </ul>	•		

Past Hx of TB	$\Box$ Yes	$\square$ No

# Sx & Sign

$\Box$ Fever (duration : )	$\Box$ Cough (duration : )
□ Sputum (duration : )	$\Box$ Weight loss (duration : )
$\Box$ Night sweat (duration : )	□ Dyspnea (duration : )
□ Chest pain (duration : )	$\Box$ Others ( )

#### Site of Infection

 $\square$  Pulmonary

□ Extrapulmonary (Pleura, Liver, Spleen, BM, CNS, L/N, Others ( ))

□ Disseminated (involved organs : )

#### Anti TB medication

Duration of Med	ication	( ) mo	onths			
Regimen	□ INH	□ RFP	□ EMB	$\square PZ$	$\Box$ others (	)
Change to 2nd line drugs?		•	□ Yes		□ No	
If yes, the reasons :		the regi	men :	du	ration :	

# **Response to anti-TB medication**

$\Box$ Cure of TB $\Box$ Improv	ement of TB	Aggravation of TB	□ Death due to TB
---------------------------------	-------------	-------------------	-------------------

#### **Events during anti-TB medication**

- $\Box$  IRIS, site :
- $\Box$  Drug toxicity ()
- $\Box$  Others ( )

# **Results of susceptibility test (Senstive, Resistant)**

INH (S, R),	RFP $(S, R)$	MBT (S, R),	PZ (S, R),	
OFX (S, R),	CS (S, R),	SM (S, R),	PAS (S, R),	
Prithionamide (S, R),		Enviomycin (Tuberlactinomycin) (S, R),		
Others () (S, R),		Others () (S, R)		